Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Gentibio, Inc. secured a $1,150,749 NIH SBIR/STTR award: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke
PRIVATEJul 08, 2026•about 1 month ago
Amount Raised
$1.15 Million
Round Type
Grant
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
National Institutes Of Health
Description
ABSTRACT In the U.S., nearly 800,000 individuals experience a stroke each year, predominantly ischemic strokes. The economic burden of stroke is staggering, with projected stroke-related medical costs in the U.S. expected to surpass $94 billion by 2035. This underscores the urgent need for effective therapies to address this significant public health challenge
Related People
Suggested for you
2 contactsVerified contactsNo contacts on file at GentiBio yet.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Watching GentiBio? See every signal — funding, hires, M&A, contracts, sentiment.
Book a demoChoose your plan